Vedanta Biosciences

Company Overview

A Cambridge, Massachusetts-based late clinical-stage biopharmaceutical company developing oral therapies built from defined bacterial consortia, with a pivotal Phase III trial for recurrent C. difficile infection approaching a first-half 2027 readout. Vedanta is trying to establish defined bacterial consortia as a reproducible, rationally designed drug class, distinct from the donor-derived fecal transplant products that first validated microbiome restoration as a therapeutic concept. Its pipeline spans recurrent C. difficile infection, ulcerative colitis, and antimicrobial resistance, with lead asset VE303 now in a global registrational study enrolling at more than 150 sites across approximately 20 countries.

Headquarters and Global Presence

Vedanta is headquartered in Cambridge, Massachusetts. Its RESTORATiVE303 trial operates across more than 150 sites in approximately 20 countries, giving the program a genuinely global enrollment footprint at a stage where many microbiome companies remain US-centric. The company has built end-to-end cGMP manufacturing capability scaled for commercial launch.

Founding and History

Vedanta was founded as part of PureTech Health, the Boston-based biopharma founder and operator. A further $106.5 million financing was announced to advance its defined bacterial consortia pipeline before the most recent $60 million raise in August 2026.

Therapy Areas and Focus

Vedanta's primary focus is gastrointestinal disease, where dysbiosis in the gut microbiome is implicated in both recurrent infections and chronic inflammatory conditions. Recurrent Clostridioides difficile infection, the target for VE303, kills tens of thousands of patients annually in the US alone and has historically been difficult to prevent after antibiotic treatment. VE202 addresses ulcerative colitis, an indication where current biologic and small-molecule therapies leave a substantial proportion of patients without adequate disease control. VE707 extends the platform into antimicrobial resistance, targeting prevention of multidrug-resistant infections.

Technology Platforms and Modalities

Vedanta's product engine centers on the rational design of defined bacterial consortia, meaning fixed combinations of specific, characterized bacterial strains rather than variable donor-derived material. The engine draws on one of the largest libraries of bacteria isolated from the human microbiome, paired with clinical datasets and proprietary capabilities in consortium design. The approach allows reproducible manufacturing and consistent dosing, which fecal microbiota transplants cannot reliably offer. End-to-end cGMP manufacturing at commercial launch scale is built in, removing a common late-stage execution risk in the live biotherapeutic category.

Key Pipeline and Programs

VE303 is Vedanta's lead asset: an orally administered live biotherapeutic product comprising a defined consortium of eight bacterial strains, intended for the prevention of recurrent Clostridioides difficile infection following antibiotic treatment. It is described as a potential first-in-class product in its defined-consortium form. The pivotal Phase III RESTORATiVE303 study has crossed 80% enrollment across more than 150 global sites, with topline efficacy data expected in the first half of 2027. A positive readout would position VE303 for regulatory submission in a market where only donor-derived products currently hold approval.

VE202 is in a Phase II trial for the treatment of ulcerative colitis. The program applies the same defined-consortium rationale to a chronic inflammatory indication, where modulating the gut microbiome is hypothesized to reduce mucosal inflammation through immunological mechanisms.

VE707 is an earlier-stage candidate targeting prevention of multidrug-resistant infections. CARB-X awarded Vedanta $3.9 million to advance VE707 toward a first-in-human study, recognizing its potential role in the antimicrobial resistance space.

Recent Developments

On 5 August 2026, Vedanta announced it had secured $60 million in funding: a $40 million investment round led by AMR Action Fund and BNP Paribas Asset Management Alts, plus $20 million drawn through its existing BARDA contract. The $40 million was received in two tranches, approximately $18 million in Q1 2026 and $22 million in Q2 2026. Two new board appointments were announced alongside the financing. RESTORATiVE303 has since crossed the 80% enrollment mark, with topline data now expected in the first half of 2027.

Key Personnel

Bernat Olle, PhD, serves as co-founder and Chief Executive Officer, driving the company's strategy since its founding within PureTech Health. Jeffrey Silber, MD, is Chief Medical Officer, overseeing the clinical programs including RESTORATiVE303 and VE202. Christof Marre serves as Senior Vice President and Head of Commercial, a role that signals Vedanta's intent to build launch readiness ahead of the 2027 Phase III readout.

Strategic Partnerships

BARDA has provided non-dilutive funding through a contract from which Vedanta drew $20 million as part of its August 2026 raise, reflecting the government's interest in microbiome-based approaches to infectious disease. AMR Action Fund, the large-scale antimicrobial resistance investment vehicle, is a lead investor and recurring supporter of the company. CARB-X awarded $3.9 million specifically to advance VE707 toward first-in-human testing.

FAQ Section